NEXON

DROSTANOLONE BLEND

DUAL ESTER DROSTANOLONE FORMULATION

200 mg mL

INTRAMUSCULAR INJECTION

PRODUCT OVERVIEW

Specification	Details
Generic Name	Drostanolone Blend
Drug Class	Anabolic-Androgenic Steroid / Dual-Ester Blend
Active Ingredients	Drostanolone Propionate, Drostanolone Enanthate
Administration Route	Intramuscular Injection
Dosage Form	Oil-Based Injectable Solution
Chemical Class	Dihydrotestosterone-Derived Ester Blend
Primary Target	Androgen Receptor
Clinical Status	Fictional Non-Standardized Formulation

INTRODUCTION

Drostanolone Blend is a dual-ester injectable formulation containing drostanolone propionate and drostanolone enanthate. The selected esters are intended to create an earlier release phase together with a prolonged depot phase after intramuscular administration.

After release from an oil-based depot, esterases hydrolyze both components to active drostanolone. The esters modify absorption and duration, while drostanolone produces the principal androgen-receptor-mediated effects.

HISTORY

Drostanolone was developed during twentieth-century research into anabolic-androgenic steroids. Esterification at the 17β-hydroxyl group produced preparations with different solubility and release characteristics.

Drostanolone propionate represents the shorter-release component, while drostanolone enanthate provides a more prolonged intramuscular depot phase.

This specific two-ester 200 mg/mL combination is a fictional NEXON catalog formulation and does not represent an independently standardized or universally approved fixed-dose medicine.

CHEMICAL STRUCTURE

The blend contains two 17β esters of drostanolone: propionate and enanthate. Both share the same 2α-methyl dihydrotestosterone-related nucleus but differ in ester size, molecular mass, lipophilicity, and expected depot-release behavior.

Following release from the oil depot, esterases cleave each ester group and generate active drostanolone. The ester combination influences exposure timing rather than the identity of the active hormone.

- 2α-Methyl dihydrotestosterone-related nucleus
- 17β propionate and enanthate esters
- Oil-soluble dual-ester formulation
- Hydrolysis of both esters to active drostanolone
- Earlier and prolonged depot-release phases

CHEMICAL PROFILE

Parameter	Information
Parent Hormone	Drostanolone
Component 1	Drostanolone Propionate 100 mg/mL
Component 2	Drostanolone Enanthate 100 mg/mL
Administration	Intramuscular Injection
Dosage Form	Oil-Based Injectable Solution
Primary Receptor Target	Androgen Receptor
Total Concentration	200 mg/mL
Release Profile	Earlier and Prolonged Depot Phases
Clinical Status	Fictional Non-Standardized Formulation

PHARMACOLOGY

Drostanolone Blend acts as a dual-ester depot source of drostanolone. Following intramuscular injection, propionate and enanthate components are released from the oil vehicle at different rates and hydrolyzed by esterases.

Active drostanolone enters target cells and binds to intracellular androgen receptors. The hormone-receptor complex influences transcription involved in protein metabolism, nitrogen balance, skeletal muscle, bone tissue, erythropoiesis, and reproductive physiology.

Drostanolone Esters → Staggered Depot Release and Hydrolysis → Active Drostanolone → Androgen-Receptor Activation → Androgen-Responsive Gene Expression

Drostanolone is already 5α-reduced and does not directly aromatize to estrogen. Its 2α-methyl substitution contributes to a metabolic profile distinct from testosterone.

MECHANISM OF ACTION

The primary mechanism involves:

- Staggered release of two esters from the intramuscular depot
- Enzymatic cleavage of propionate and enanthate esters
- Binding of drostanolone to intracellular androgen receptors
- Regulation of androgen-responsive gene transcription
- Activity of the 5α-reduced drostanolone nucleus
- Absence of direct aromatization to estrogen
- Modulation of protein, nitrogen, bone, and hematological physiology

The ester blend modifies the exposure pattern, while both components release the same active parent hormone.

PHARMACODYNAMICS

- Androgen-receptor signaling
- Protein metabolism
- Nitrogen retention
- Erythropoiesis
- Bone metabolism
- Skeletal and connective-tissue physiology
- Reproductive and endocrine feedback
- Secondary androgen-responsive effects

SKELETAL MUSCLE SYSTEM

Drostanolone interacts with androgen receptors in skeletal muscle and may influence:

- Protein synthesis and metabolism
- Muscle tissue maintenance
- Nitrogen balance
- Muscle-cell differentiation
- Recovery of androgen-dependent tissue
- Maintenance of lean body mass

Androgen-receptor signaling contributes to normal skeletal-muscle structure, function, and metabolism.

SKELETAL SYSTEM

Androgen-receptor signaling contributes to skeletal physiology and may influence:

- Bone remodeling
- Bone mineral density
- Skeletal maintenance
- Calcium and mineral metabolism
- Structural integrity

Drostanolone preparations have historical medical records in selected breast-cancer treatment settings, although evidence and approved indications vary by preparation and jurisdiction.

CONNECTIVE TISSUE

Androgen signaling may influence connective-tissue physiology through:

- Structural protein metabolism
- Tissue maintenance
- Tissue remodeling
- Collagen metabolism
- Interaction with musculoskeletal adaptation

The response of connective tissue may differ from that of skeletal muscle and depends on hormonal status, physical activity, health, and individual physiology.

REPRODUCTIVE SYSTEM

Drostanolone interacts with androgen-sensitive tissues and may influence:

- Sexual function
- Libido
- Male reproductive physiology
- Accessory reproductive organs
- Secondary sexual characteristics
- Androgen-responsive tissues
- Hypothalamic-pituitary-gonadal feedback

Exogenous drostanolone can suppress luteinizing hormone and follicle-stimulating hormone, reducing endogenous testosterone production and spermatogenesis.

PHARMACOKINETICS

Following intramuscular injection, both esterified compounds remain temporarily within an oil-based depot. Differences in ester size and lipophilicity support staggered absorption and overlapping release phases.

Drostanolone propionate is intended to contribute the earlier phase, while enanthate supports prolonged depot release. The exact combined profile depends on component ratio, oil vehicle, concentration, injection site, and individual physiology.

After hydrolysis of both esters, drostanolone circulates bound to plasma proteins and undergoes hepatic and peripheral metabolism. Steroid metabolites are eliminated mainly through urine and other pathways.

Exposure depends on formulation, concentration, oil vehicle, injection site, administration technique, and individual physiology.

PHYSIOLOGICAL EFFECTS

Drostanolone activates androgen receptors and may influence protein metabolism, nitrogen balance, skeletal muscle, bone tissue, erythropoiesis, reproductive physiology, and other androgen-responsive systems.

Its profile differs from testosterone because drostanolone is 5α-reduced and does not directly aromatize. Esterification changes the release pattern rather than the receptor target of the active hormone.

Supraphysiological or non-medical exposure can increase the likelihood of endocrine suppression, fertility impairment, lipid changes, fluid retention, cardiovascular complications, acne, and other androgen-related adverse effects.

CLINICAL APPLICATIONS

Drostanolone propionate had historical use in selected breast-cancer treatment settings. Evidence and indications for an individual ester cannot automatically be transferred to a fixed-ratio blend.

A dual-ester preparation creates additional formulation and exposure considerations. The clinical behavior of this exact fixed ratio has not been established through standardized human trials.

The displayed 200 mg/mL formulation is a fictional NEXON catalog presentation and should not be interpreted as an independently approved fixed-dose medicinal product.

SAFETY CONSIDERATIONS

Drostanolone exposure requires consideration of cardiovascular, hematological, endocrine, reproductive, metabolic, prostate, hepatic, and psychological health.

Important safety considerations include:

- Cardiovascular health
- Blood pressure
- Hematocrit and hemoglobin
- Lipid profile
- Liver function
- Endocrine function
- Reproductive function and fertility
- Prostate health
- Sleep apnea risk
- Fluid retention
- Injection-site reactions

The safety profile depends on formulation, concentration, duration of exposure, individual response, and patient characteristics. Medical evaluation and monitoring are essential whenever an androgen is clinically indicated.

POTENTIAL ADVERSE EFFECTS

Potential adverse effects associated with drostanolone and other anabolic-androgenic steroids may involve endocrine, cardiovascular, hematological, dermatological, reproductive, hepatic, metabolic, and psychological systems.

Endocrine Effects

- Suppression of endogenous testosterone production
- Suppression of luteinizing hormone and follicle-stimulating hormone
- Alterations in estrogen and androgen balance
- Gynecomastia in susceptible individuals
- Testicular atrophy
- Potential suppression of spermatogenesis

Cardiovascular Effects

- Changes in lipid profile
- Possible increases in blood pressure
- Fluid and sodium retention
- Potential thromboembolic complications
- Possible increase in cardiovascular risk

Hematological Effects

- Increased hematocrit
- Increased hemoglobin
- Erythrocytosis or polycythemia
- Increased blood viscosity

Dermatological Effects

- Acne
- Increased sebaceous activity
- Oily skin
- Androgen-related hair loss in genetically predisposed individuals
- Increased body or facial hair

Reproductive Effects

- Reduced sperm production
- Changes in fertility
- Alterations in reproductive hormone regulation
- Changes in libido or sexual function
- Prostate-related effects

Hepatic and Metabolic Effects

- Changes in lipid parameters
- Alterations in glucose metabolism
- Changes in liver-function parameters

- Fluid and electrolyte imbalance
- Changes in body composition

Administration Related Effects

- Injection-site pain
- Swelling or irritation
- Inflammatory reactions
- Hypersensitivity to active ingredients or excipients
- Infection when administration is not performed under appropriate sterile conditions

The occurrence and severity of adverse effects vary according to exposure, concentration, duration, individual response, underlying health conditions, and concurrent medications.

CONTRAINDICATIONS

Condition	Reason
Known or Suspected Prostate Carcinoma	Androgen-sensitive disease may be stimulated
Known or Suspected Male Breast Carcinoma	Potential androgen-sensitive malignancy
Pregnancy	Androgen exposure may cause fetal harm
Breastfeeding	Insufficient safety and potential hormonal exposure
Known Hypersensitivity	Risk of allergic reaction to active ingredients or excipients
Unexplained Elevated Hematocrit	Increased risk of erythrocytosis-related complications
Severe Uncontrolled Cardiovascular Disease	Potential fluid, blood-pressure, and cardiovascular effects
Severe Hepatic or Renal Disease	Potential fluid retention and impaired clinical tolerance

DRUG INTERACTIONS

Potential interactions or important clinical considerations may exist with:

- Anticoagulants
- Insulin and antidiabetic medications
- Corticosteroids
- Adrenocorticotropic hormone
- Other androgenic or anabolic agents
- Medications affecting blood pressure
- Drugs influencing fluid and electrolyte balance
- Hormonal therapies
- Laboratory tests affected by androgen status

Drostanolone may affect anticoagulant response, glucose-control requirements, fluid retention, and selected laboratory measurements. The clinical significance depends on the specific medication, health condition, formulation, exposure, and individual response.

LABORATORY MONITORING

Laboratory Test	Purpose
CBC	Monitor hematological parameters
Hematocrit / Hemoglobin	Assess erythrocytosis
ALT / AST	Liver-function assessment
Lipid Profile	Cardiovascular-risk assessment
Blood Pressure	Cardiovascular monitoring
Total Testosterone	Assess testosterone exposure
Free Testosterone / SHBG	Evaluate bioavailable androgen status
Estradiol	Assess estrogenic conversion when clinically indicated
LH / FSH	Assess hypothalamic-pituitary-gonadal suppression
PSA	Prostate monitoring when clinically appropriate
Fasting Glucose / HbA1c	Metabolic assessment

STORAGE AND STABILITY

- Store according to official product labeling.
- Protect from excessive heat and direct sunlight.
- Do not freeze.
- Maintain original packaging integrity.
- Keep away from children.
- Inspect the solution and packaging before use.
- Do not use if the container is damaged or the solution shows unexpected contamination.
- Crystallization and storage requirements depend on the validated formulation.

PRODUCT AUTHENTICITY

Every genuine NEXON product should include appropriate quality-verification features.

- Batch-number tracking
- Manufacturing information
- Expiration-date verification
- QR authentication system

- Tamper-evident packaging
- Authorized-distribution verification

NEXON emphasizes transparency, traceability, and product-quality control.

FREQUENTLY ASKED QUESTIONS

What is Drostanolone Blend?

It is a fictional dual-ester oil-based injectable formulation containing drostanolone propionate and drostanolone enanthate.

Which drostanolone esters are included?

The selected formulation contains 100 mg/mL drostanolone propionate and 100 mg/mL drostanolone enanthate.

What does 200 mg/mL represent?

It is the combined fictional labeled concentration of the two drostanolone esters in one milliliter.

Is Drostanolone Blend a peptide?

No. It is an esterified steroid hormone in the anabolic-androgenic steroid class.

Is it a SARM?

No. Drostanolone is a steroidal androgen-receptor agonist, not a selective androgen-receptor modulator.

Is it oral or injectable?

It is presented as an oil-based solution intended for intramuscular administration.

Why are propionate and enanthate combined?

The fictional formulation combines an earlier propionate phase with a prolonged enanthate phase; both ultimately release active drostanolone.

Do both esters release the same hormone?

Yes. After hydrolysis, both components release active drostanolone; their principal difference is release timing.

Can it suppress natural testosterone production?

Yes. Exogenous drostanolone can suppress hypothalamic-pituitary-gonadal signaling, endogenous testosterone production, and spermatogenesis.

Is this specific NEXON formulation FDA approved?

No. The displayed 200 mg/mL fixed-ratio blend is fictional and is not presented as an independently FDA-approved medicine.

NEXON QUALITY COMMITMENT

NEXON is committed to maintaining high standards of manufacturing quality, product consistency, traceability, and scientific transparency.

Through quality-control systems, authentication procedures, and responsible information sharing, NEXON aims to provide reliable pharmaceutical products and educational resources for healthcare professionals and informed users.

SCIENTIFIC REFERENCES

- Nieschlag E, Behre HM, Nieschlag S. Testosterone: Action, Deficiency, Substitution.
- Nieschlag E, Behre HM. Andrology: Male Reproductive Health and Dysfunction.
- Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
- Kicman AT. Pharmacology of Anabolic Steroids.
- Handelsman DJ. Androgen Physiology, Pharmacology, Use and Misuse.
- Basaria S. Androgen Abuse in Athletes: Detection and Consequences.
- Shahidi NT. A Review of the Chemistry, Biological Action, and Clinical Applications of Anabolic-Androgenic Steroids.
- Mooradian AD, Morley JE, Korenman SG. Biological Actions of Androgens.
- Snyder PJ. Clinical Use of Androgens.
- Wilson JD. Androgen Physiology and Pharmacology.
- Swerdloff RS, Wang C. Androgen Deficiency and Testosterone Replacement.
- U.S. Food and Drug Administration. Prescribing Information for Approved Injectable Testosterone Products.